Bouwer C, Stein D J
Dept. of Psychiatry, University of Stellenbosch, Tygerberg, South Africa.
J Affect Disord. 1998 Apr;49(1):79-82. doi: 10.1016/s0165-0327(97)00182-1.
There is increasing evidence that social phobia responds to treatment with selective serotonin reuptake inhibitors (SSRIs). However, the efficacy of citalopram, the most selective of the SSRIs, in social phobia has not been well documented.
Citalopram was used on an open-label naturalistic basis in 22 social phobia patients presenting for treatment (40 mg daily for 12 weeks). Patients were rated with the Liebowitz Social Anxiety Scale and the Clinical Global Impressions (CGI) scale.
Ratings on the Liebowitz Social Anxiety Scale and the CGI were significantly improved after treatment. A total of 86% of patients were responders at week 12.
Open, uncontrolled study.
Citalopram appears to be effective in the treatment of social phobia. A controlled trial is warranted to confirm these data. The role of serotonin in social phobia deserves further study.
越来越多的证据表明社交恐惧症对选择性5-羟色胺再摄取抑制剂（SSRI）治疗有效。然而，作为SSRI中选择性最强的西酞普兰治疗社交恐惧症的疗效尚未得到充分证实。
对22例前来治疗的社交恐惧症患者采用开放标签自然观察法使用西酞普兰（每日40毫克，共12周）。采用利博维茨社交焦虑量表和临床总体印象（CGI）量表对患者进行评分。
治疗后利博维茨社交焦虑量表和CGI评分显著改善。在第12周时，共有86%的患者有反应。
开放、非对照研究。
西酞普兰似乎对社交恐惧症有效。有必要进行对照试验以证实这些数据。5-羟色胺在社交恐惧症中的作用值得进一步研究。
